Medical Devices
Blood Thawing System Market Size, 2024-2033
USD Billion
The figures are in the full report. Request a free sample ↗
Market overview
| Study Period | 2024 - 2033 |
|---|---|
| Historic Year | 2024 |
| Base Year | 2025 |
| Forecast Period | 2026 - 2033 |
| Market Size (Base Year) | USD 0.18 Billion |
| Market Size (Forecast Year) | USD 0.29 Billion |
| Growth Rate (CAGR) | 6.0 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Pages from the sample report. Figures are shown as XX here; the full report has them.
See the full sample: Request a free sample ↗
This report covers the blood thawing system market: devices that thaw frozen plasma, blood components and cryopreserved cells safely and at a controlled temperature before use, including wet and dry plasma thawers and automated thawers for stem cells, cell therapies, cord blood and reproductive samples, with their consumables and service. The market is valued at manufacturers' selling prices.
Controlled thawing protects the quality of plasma and the survival of cells, and reduces the risk of contamination compared with open water baths.
Hospitals and blood banks need fast, reliable thawing of plasma for trauma, surgery and bleeding disorders, and many are replacing water baths with dry thawers that cut contamination risk and cleaning work.
The growth of stem cell transplants, CAR T-cell and gene therapies, which are shipped frozen and thawed at the bedside, is creating demand for automated, standardised cell thawers, while fertility clinics thaw embryos, eggs and sperm.
However, thawers last many years, hospital equipment budgets are tight, and lower-cost water baths remain common in developing countries.
The global Blood Thawing System market is mainly classified based on type, product type, sample type and end-user. By type, the market is divided into manual and automated devices. By product type, it is divided into dry and wet plasma thawers. By sample type, it covers blood, plasma, stem cells, whole blood and red blood cells, platelets, embryos, ovum and semen. By end-user, it covers blood banks and transfusion centers, hospitals and diagnostic laboratories, cord blood and stem cell banks, research and academic institutes, biotechnology and pharmaceutical companies and tissue banks.
Automated devices account for the largest share, and dry plasma thawers are gaining share from wet thawers.
Plasma is the largest sample type and blood banks and transfusion centers the largest end-user, while stem cells and cell therapies, used by biotechnology companies and cell therapy centres, grow fastest.
North America is the largest market, supported by large blood services, trauma care and most of the world's approved cell therapies.
Europe is the second-largest market, with strong blood services and plasma thawer makers. Asia-Pacific is expected to grow fastest as China and India expand blood services, hospitals and cell therapy production.
Some of the major competitors in the global Blood Thawing System market include Helmer Scientific, Barkey GmbH, Sarstedt, Thermo Fisher Scientific, BioLife Solutions (ThawSTAR), Cytiva, Sartorius, Boekel Scientific, B Medical Systems, Fresenius Kabi, Haier Biomedical, and Cardinal Health.
The Blood Thawing System market is moderately concentrated. Helmer Scientific, Barkey, Sarstedt, Boekel and B Medical Systems lead in plasma thawers, while BioLife Solutions, Cytiva, Thermo Fisher Scientific and Sartorius lead in automated cell thawing.
Ans: The Blood Thawing System market was valued at USD 0.18 billion in 2025 and is projected to reach USD 0.29 billion by 2033, at a CAGR of 6.0% during the forecast period.
Ans: Automated thawers for cell and gene therapies, replacement of water baths with dry thawers and expanding blood services in Asia are major opportunities.
Ans: Demand for safe, fast plasma thawing and the growth of cell therapies are the main growth drivers.
Ans: North America is expected to have the largest share, while Asia-Pacific is expected to grow fastest.
Ans: Dry plasma thawers are expected to gain share and lead the market.
In September 2025 the US Department of Commerce opened a national security investigation into imports of medical devices and equipment, which could lead to tariffs on imported medical devices.
Many plasma and cell thawers sold in the United States are made in Europe or Asia, so tariffs would raise prices for blood banks and hospitals and could delay replacement of older equipment.
Makers with plants in the United States would gain, and some suppliers may move assembly closer to their customers.
This report assumes any tariffs raise prices without cutting demand much, as thawers are essential and a small part of blood bank budgets.
Backed by 1 million+ hours of research experience across the industries we cover.
Domains covered
Countries covered
Committed to timely delivery
Projects delivered